Pushkar Kanade, MD
Internal Medicine · Cleveland, OHNPI 1144506445
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,825 of the $31,495 with a category attached, or 69.3%. Amgen accounts for 65.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $15,559 and has fallen 65.8% since, to $5,316 in 2025. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $288.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Ardelyx, Inc.$10K
- Fresenius USA Marketing, Inc.$211
- Travere Therapeutics, Inc.$196
- Otsuka America Pharmaceutical, Inc.$195
- Mallinckrodt Hospital Products Inc.$136
- plus $366 from 8 others
Across 249 payments — averaging $2896.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$173K
- Boehringer Ingelheim Pharma GmbH & Co.kg$160K
- CSL Behring$152K
- Akebia Therapeutics Inc$125K
- Boehringer Ingelheim International GmbH$112K
What the payments were for
- Consulting fees$3,60011%
- Speaking & faculty fees$21,82569%
- Travel & lodging$3,70512%
- Food & beverage$2,1657%
- Education$2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 41 | $20,474 |
| Ardelyx, Inc. | 17 | $9,916 |
| Fresenius USA Marketing, Inc. | 13 | $211 |
| Travere Therapeutics, Inc. | 12 | $196 |
| Otsuka America Pharmaceutical, Inc. | 2 | $195 |
| Mallinckrodt Hospital Products Inc. | 5 | $136 |
| AstraZeneca(2 entities) | 6 | $105 |
| Aurinia Pharma U.S., Inc. | 5 | $101 |
| Bayer | 2 | $38 |
| Calliditas Therapeutics US Inc. | 2 | $34 |
| Vifor Pharma, Inc. | 1 | $29 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$19,792
- XPHOZAH 30 MG$9,721
- JYNARQUE$191
How this compares
$31,495 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 51 | $176,139 |
| JardianceEmpagliflozin | 201 | $123,620 |
| VelphoroSucroferric Oxyhydroxide | 25 | $89,775 |
| Sevelamer Carbonate | 157 | $44,574 |
| KerendiaFinerenone | 51 | $34,087 |
| RenvelaSevelamer Carbonate | 20 | $34,064 |
| FarxigaDapagliflozin Propanediol | 26 | $17,551 |
| VeltassaPatiromer Calcium Sorbitex | 45 | $14,135 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $9,778 |
| EntrestoSacubitril/Valsartan | 12 | $8,121 |
| Midodrine Hcl | 56 | $5,942 |
| Potassium Citrate ErPotassium Citrate | 94 | $5,619 |
| Calcitriol | 452 | $4,335 |
| Tamsulosin Hcl | 158 | $3,165 |
| Bumetanide | 57 | $2,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $211 | $89,77525 claims |
| BayerKerendia | $38 | $34,08751 claims |
| AstraZenecaFarxiga, Lokelma | $105 | $27,32940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cleveland
- Cyrus HarrisCleveland$726K
- Marina MagreyCleveland$312K
- Joshua LonginowCleveland$241K
- Emad MansoorCleveland$219K
- Syed BukhariCleveland$165K
- Vadim KoshkinCleveland$159K
- Suresh Kumar BalasubramanianCleveland$148K
- Christine Tanaka-EspositoCleveland$123K
- Carla HarwellCleveland$75K
- Amr MohamedCleveland$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.